RETRACTED: Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines

Gugu, Thaddeus Harrison; Eze, Christopher Osita; Kenechukwu, Franklin Chimaobi; Bintang, Maria; Patil, Sanjay B.; Basarkar, Ganesh D.; Attama, Anthony A.; Ibezim, EC; Upasani, Chandrashekhar; Srichana, Teerapol

doi:10.1016/j.heliyon.2023.e16963

Cited by 4 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a promising safety profile of the nanodelivery system was demonstrated using in vitro and in vivo (Daphnia magna and zebrafish) toxicity assays [63]. A different strategy was reported by Gugu et al [64] using lipid nanoparticles to load prodigiosin for parenteral administration to eventually treat triple-negative breast, lung, and colon cancers.…”

Section: Passive Targetingmentioning

confidence: 99%

The Golgi Apparatus as an Anticancer Therapeutic Target

Martins,

Vieira,

Pereira-Leite

et al. 2023

Biology

View full text Add to dashboard Cite

Although the discovery of the Golgi apparatus (GA) was made over 125 years ago, only a very limited number of therapeutic approaches have been developed to target this complex organelle. The GA serves as a modification and transport center for proteins and lipids and also has more recently emerged as an important store for some ions. The dysregulation of GA functions is implicated in many cellular processes associated with cancer and some GA proteins are indeed described as cancer biomarkers. This dysregulation can affect protein modification, localization, and secretion, but also cellular metabolism, redox status, extracellular pH, and the extracellular matrix structure. Consequently, it can directly or indirectly affect cancer progression. For these reasons, the GA is an appealing anticancer pharmacological target. Despite this, no anticancer drug specifically targeting the GA has reached the clinic and few have entered the clinical trial stage. Advances in nanodelivery approaches may help change this scenario by specifically targeting tumor cells and/or the GA through passive, active, or physical strategies. This article aims to examine the currently available anticancer GA-targeted drugs and the nanodelivery strategies explored for their administration. The potential benefits and challenges of modulating and specifically targeting the GA function in the context of cancer therapy are discussed.

show abstract

Section: Passive Targetingmentioning

confidence: 99%

The Golgi Apparatus as an Anticancer Therapeutic Target

Martins,

Vieira,

Pereira-Leite

et al. 2023

Biology

View full text Add to dashboard Cite

show abstract

“…Additionally, acute toxicity was studied in rats to assess the safety. The results showed that these nanoparticles effectively inhibited the growth of the cancer cells, suggesting that prodigiosin, when delivered in nanoparticle form, could be a promising therapeutic agent due to its enhanced delivery and potent anticancer properties [79].…”

Section: Miscellaneous Natural Compoundsmentioning

confidence: 99%

Lipid Nanoparticles in Lung Cancer Therapy

Omidian,

Gill,

Cubeddu

2024

Pharmaceutics

View full text Add to dashboard Cite

This manuscript explores the use of lipid nanoparticles (LNPs) in addressing the pivotal challenges of lung cancer treatment, including drug delivery inefficacy and multi-drug resistance. LNPs have significantly advanced targeted therapy by improving the precision and reducing the systemic toxicity of chemotherapeutics such as doxorubicin and paclitaxel. This manuscript details the design and benefits of various LNP systems, including solid lipid–polymer hybrids, which offer controlled release and enhanced drug encapsulation. Despite achievements in reducing tumor size and enhancing survival, challenges such as manufacturing complexity, biocompatibility, and variable clinical outcomes persist. Future directions are aimed at refining targeting capabilities, expanding combinatorial therapies, and integrating advanced manufacturing techniques to tailor treatments to individual patient profiles, thus promising to transform lung cancer therapy through interdisciplinary collaboration and regulatory innovation.

show abstract